Hronična mijeloidna leukemija (Serbian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Hronična mijeloidna leukemija" in Serbian language version.

refsWebsite

Global rank Serbian rank

4^th place

8^th place

2^nd place

4^th place

doi.org

Tefferi A (2006). „Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era”. Hematology Am Soc Hematol Educ Program. 2006: 240—245. PMID 17124067. doi:10.1182/asheducation-2006.1.240.
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM (2007). „Current and emerging treatment options in chronic myeloid leukemia”. Cancer. 109 (11): 2171—2181. PMID 17431887. doi:10.1002/cncr.22661.
Kimura S, Ashihara E, Maekawa T (2006). „New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia”. Current Pharmaceutical Biotechnology. 7 (5): 371—379. PMID 17076652. doi:10.2174/138920106778521532.

Faderl S, Talpaz M, Estrov Z, Kantarjian HM (1999). „Chronic myelogenous leukemia: biology and therapy”. Annals of Internal Medicine. 131 (3): 207—219. PMID 10428738.
Moloney WC (1987). „Radiogenic leukemia revisited”. Blood. 70 (4): 905—908. PMID 3477299.
Tefferi A (2006). „Classification, diagnosis and management of myeloproliferative disorders in the JAK2V617F era”. Hematology Am Soc Hematol Educ Program. 2006: 240—245. PMID 17124067. doi:10.1182/asheducation-2006.1.240.
Jabbour E, Cortes JE, Giles FJ, O'Brien S, Kantarjian HM (2007). „Current and emerging treatment options in chronic myeloid leukemia”. Cancer. 109 (11): 2171—2181. PMID 17431887. doi:10.1002/cncr.22661.
Kimura S, Ashihara E, Maekawa T (2006). „New tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia”. Current Pharmaceutical Biotechnology. 7 (5): 371—379. PMID 17076652. doi:10.2174/138920106778521532.